Ubs Group Ag Alzamend Neuro, Inc. Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.19 - $0.52 $1,456 - $3,987	7,668 Added 2960.62%	7,927 $1,000
Q2 2023 Aug 11, 2023	SELL	$0.49 - $0.77 $1,329 - $2,089	-2,714 Reduced 91.29%	259 $0
Q1 2023 May 12, 2023	SELL	$0.37 - $0.71 $2,288 - $4,392	-6,186 Reduced 67.54%	2,973 $1,000
Q4 2022 Feb 08, 2023	SELL	$0.53 - $222.0 $4,899 - $2.05 Million	-9,244 Reduced 50.23%	9,159 $5,000
Q3 2022 Nov 10, 2022	SELL	$0.88 - $178.5 $1,653 - $335,401	-1,879 Reduced 9.26%	18,403 $22,000
Q2 2022 Aug 10, 2022	BUY	$0.82 - $1.2 $3,448 - $5,047	4,206 Added 26.16%	20,282 $18,000
Q1 2022 May 16, 2022	BUY	$0.91 - $2.23 $12,285 - $30,105	13,500 Added 524.07%	16,076 $20,000
Q4 2021 Feb 14, 2022	SELL	$1.9 - $3.08 $267 - $434	-141 Reduced 5.19%	2,576 $5,000
Q3 2021 Nov 15, 2021	BUY	$2.28 - $7.68 $59 - $199	26 Added 0.97%	2,717 $8,000
Q2 2021 Aug 13, 2021	BUY	$8.12 - $13.5 $21,850 - $36,328	2,691 New	2,691 $24,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $159M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.